




Figure S1. The pooled proportion of second primary neoplasm of prostate in melanoma survivors.




Figure S2. The pooled proportion of second primary neoplasm of breast in melanoma survivors.




Figure S3. The pooled proportion of second primary neoplasm of colorectum in melanoma survivors.

melanoma survivors.




Figure S4. The pooled proportion of second primary neoplasm of bronchus and lung in melanoma survivors.




Figure S5. The pooled proportion of second primary neoplasm of colon in melanoma survivors.




Figure S6. The pooled proportion of second primary neoplasm of corpus uteri in melanoma survivors.




Figure S7. The pooled proportion of second primary neoplasm of lymphoma in melanoma survivors.




Figure S8. The pooled proportion of second primary neoplasm of bladder in melanoma survivors.




Figure S9. The pooled proportion of second primary neoplasm of rectum in melanoma survivors.




Figure S10. The pooled proportion of second primary neoplasm of Non Hodgkin lymphoma in melanoma survivors.




Figure S11. The pooled proportion of second primary neoplasm of kidney in melanoma survivors.




Figure S12. The pooled proportion of second primary neoplasm of ovary in melanoma survivors.




Figure S13. The pooled proportion of second primary neoplasm of stomach in melanoma survivors.




Figure S14. The pooled proportion of second primary neoplasm of pancreas in melanoma survivors.




Figure S15. The pooled proportion of second primary neoplasm of leukaemia in melanoma survivors.




Figure S16. The pooled proportion of second primary neoplasm of thyroid gland in melanoma survivors.




Figure S17. The pooled proportion of second primary neoplasm of lymphoid leukaemia in melanoma survivors.




Figure S18. The pooled proportion of second primary neoplasm of multiple myeloma in melanoma survivors.




Figure S19. The pooled proportion of second primary neoplasm of cervix uteri in melanoma survivors.

melanoma survivors.




Figure S20. The pooled proportion of second primary neoplasm of liver in melanoma survivors.




Figure S21. The pooled proportion of second primary neoplasm of myeloid leukaemia in melanoma survivors.




Figure S22. The pooled proportion of second primary neoplasm of testis in melanoma survivors.




Figure S23. The pooled proportion of second primary neoplasm of Hodgkin lymphoma in melanoma survivors.




Figure S24. The pooled proportion of second primary neoplasm of nasal cavity and middle ear in melanoma survivors.




Figure S25. The pooled SIR of SPM of prostate in melanoma survivors without restriction to lag time.




Figure S26. The pooled SIR of SPM of breast in melanoma survivors without restriction to lag time.




Figure S27. The pooled SIR of SPM of colorectum in melanoma survivors without restriction to lag time.




Figure S28. The pooled SIR of SPM of bronchus and lung in melanoma survivors without restriction to lag time.




Figure S29. The pooled SIR of SPM of colon in melanoma survivors without restriction to lag time.




Figure S30. The pooled SIR of SPM of corpus uteri in melanoma survivors without restriction to lag time.




Figure S31. The pooled SIR of SPM of lymphoma in melanoma survivors without restriction to lag time.




Figure S32. The pooled SIR of SPM of bladder in melanoma survivors without restriction to lag time.




Figure S33. The pooled SIR of SPM of rectum in melanoma survivors without restriction to lag time.




Figure S34. The pooled SIR of SPM of Non Hodgkin lymphoma in melanoma survivors without restriction to lag time.




Figure S35. The pooled SIR of SPM of kidney in melanoma survivors without restriction to lag time.




Figure S36. The pooled SIR of SPM of ovary in melanoma survivors without restriction to lag time.




Figure S37. The pooled SIR of SPM of stomach in melanoma survivors without restriction to lag time.




Figure S38. The pooled SIR of SPM of pancreas in melanoma survivors without restriction to lag time.




Figure S39. The pooled SIR of SPM of leukaemia in melanoma survivors without restriction to lag time.




Figure S40. The pooled SIR of SPM of thyroid gland in melanoma survivors without restriction to lag time.




Figure S41. The pooled SIR of SPM of lymphoid leukaemia in melanoma survivors without restriction to lag time.




Figure S42. The pooled SIR of SPM of multiple myeloma in melanoma survivors without restriction to lag time.




Figure S43. The pooled SIR of SPM of cervix uteri in melanoma survivors without restriction to lag time.




Figure S44. The pooled SIR of SPM of liver in melanoma survivors without restriction to lag time.




Figure S45. The pooled SIR of SPM of myeloid leukaemia in melanoma survivors without restriction to lag time.




Figure S46. The pooled SIR of SPM of testis in melanoma survivors without restriction to lag time.




Figure S47. The pooled SIR of SPM of Hodgkin lymphoma in melanoma survivors without restriction to lag time.




Figure S48. The pooled SIR of SPM of nasal cavity and middle ear in melanoma survivors without restriction to lag time.




Figure S49. The pooled SIR of SPM of prostate in melanoma survivors with lag time to two months.




Figure S50. The pooled SIR of SPM of breast in melanoma survivors with lag time to two months.




Figure S51. The pooled SIR of SPM of bronchus and lung in melanoma survivors with lag time to two months.




Figure S52. The pooled SIR of SPM of colon in melanoma survivors with lag time to two months.




Figure S53. The pooled SIR of SPM of lymphoma in melanoma survivors with lag time to two months.




Figure S54. The pooled SIR of SPM of Non Hodgkin lymphoma in melanoma survivors with lag time to two months.




Figure S55. The pooled SIR of SPM of kidney in melanoma survivors with lag time to two months.




Figure S56. The pooled SIR of SPM of leukaemia in melanoma survivors with lag time to two months.




Figure S57. The pooled SIR of SPM of thyroid gland in melanoma survivors with lag time to two months.




Figure S58. The pooled SIR of SPM of lymphoid leukaemia in melanoma survivors with lag time to two months.